Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platform
This study demonstrates that the CANDO platform's multitarget drug repurposing approach successfully identifies and validates novel therapeutic candidates for schizophrenia by analyzing compound-proteome interaction signatures, revealing both established and potential new mechanisms involving neurotransmitter systems and calcium signaling pathways.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine schizophrenia as a massive, tangled knot of problems in the brain. It's not just one loose thread; it's a complex mix of positive symptoms (like hallucinations), negative symptoms (like losing motivation), and cognitive issues (trouble thinking clearly). Currently, doctors have a few tools to try to untie this knot, but they often only pull on one specific thread. For many patients, this single-thread approach doesn't work well, leaving the knot tight and the patient struggling.
This paper describes a new way to find better tools using a high-tech "search engine" for drugs called CANDO.
The Problem with the Old Way
Think of traditional drug discovery like trying to fix a broken car by only looking at the engine. If the problem is actually in the tires or the brakes, focusing only on the engine won't help. Schizophrenia is like a car with issues in the engine, tires, brakes, and electronics all at once. Doctors need a tool that can see the whole car, not just one part.
The CANDO Solution: A "Fingerprint" Approach
Instead of looking at one target at a time, the CANDO platform acts like a master detective that scans a drug's entire "fingerprint."
- The Fingerprint: Every drug interacts with hundreds of different proteins in the human body. CANDO maps out every single one of these interactions to create a unique profile for each drug.
- The Match: The system then compares these fingerprints. If Drug A has a fingerprint that looks very similar to Drug B (which we know helps with a specific problem), CANDO predicts that Drug A might help with that same problem too. It's like finding a new key that looks just like an old key that fits a specific lock.
What They Found
The researchers used this system to hunt for existing drugs that could be "repurposed" (used for a new job) to treat schizophrenia. They tested their system first to make sure it worked, and it proved to be incredibly accurate—far better than random guessing.
They generated a ranked list of potential drugs and checked the medical literature to see if there was real-world evidence to back them up. They found 25 strong candidates. These weren't just random chemicals; they included familiar types of drugs like:
- Old-school antipsychotics (phenothiazines and benzamides).
- Tricyclic antidepressants.
- Benzodiazepines (often used for anxiety).
- Monoamine oxidase inhibitors.
Why These Drugs Work: The "Target" Map
The study didn't just stop at naming the drugs; it looked at why they might work by identifying the specific proteins (the "locks") they interact with.
- The Usual Suspects: As expected, many of these drugs hit the well-known targets in the brain, like dopamine and serotonin receptors.
- The New Clues: The study found some interesting new connections. For example, one drug called thiethylperazine seemed to interact heavily with proteins that handle calcium. This suggests that calcium signaling might be a hidden piece of the schizophrenia puzzle that we haven't fully appreciated yet.
- The Double Agent: Another drug, triflupromazine, was found to hit both the dopamine receptor (for psychosis) and the serotonin transporter (often linked to mood). This explains why it might be good for treating the depression that often comes with schizophrenia.
The Bottom Line
This paper shows that the CANDO platform is a powerful tool for untangling complex diseases. By looking at the whole picture of how a drug interacts with the body, rather than just one part, it successfully identified a list of existing drugs that are likely to be effective multitarget treatments for schizophrenia. It's like upgrading from a single screwdriver to a full Swiss Army knife, giving doctors a better chance of fixing the complex knot of schizophrenia.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.